News and Stories

September 12, 2023

Lab Tests for Healthy Aging

Curious about staying youthful? The secret is a healthy lifestyle. It is never too late to get started!

Read More
September 01, 2023

Celebrating Compassion and Collaboration: HNL Lab Medicine and NCC’s Back-to-School Pantry Drive

In a heartwarming display of unity and generosity, HNL Lab Medicine is thrilled to share the exciting news of its partnership with Northampton Community College (NCC) for a remarkable Back-to-School Pantry Drive.

Read More
August 28, 2023

Martin K. Till Featured on Health Care Power List

Martin K. Till, President and CEO of HNL Lab Medicine, has been named a top leader on Lehigh Valley Business’ Health Care Power List.  

Read More
August 16, 2023

Why Blood Tests Are Important for Children: Top Tests Explained

Blood tests are diagnostic tools that help pediatricians assess your child’s health. 

Read More
July 28, 2023

Hepatitis & The Different Types of Viral Infections

Did you know that viral hepatitis is a group of liver infections caused by different viruses? It is also characterized by inflammation of the liver. What does the liver do, you ask?
Read More
News and Stories

July 06, 2022
Dr. Hina Sheikh, Co-Chief, Section of Dermatopathology at HNL Lab Medicine, contributed on this case report, along with colleagues in medical, surgical and radiation oncology at LV Health Network. It was recently published in Melanoma Research Journal 2022 (article). It gives a personalized treatment roadmap on a patient with inoperable stage III melanoma, who failed multiple standard treatments but subsequently showed response to an investigational therapeutic ulixertinib. Case underscores the value of flexibility in oncologic treatment when patients have failed first line therapies or develop serious side effects. Role of pathology in tumor mutational profiling (to guide targeted therapy) and in assessment of treatment response is highlighted. As ulixertinib is formally being reviewed in multiple clinical trials for several tumor types, authors wanted to bring to attention this case (first to their knowledge) of a patient with advanced melanoma harboring the BRAF D594G mutation that was treated successfully with this ERK inhibitor. Such success stories not only give hope to oncology patients, but they also bring the collective medical community closer to our shared goal of personalized 'precision' medicine. HNL and LVHN are fully committed to this goal.